Primary and secondary alterations of immune reactivity in the elderly: Impact of dietary factors and disease

Immunological Reviews

Volumn 160, Issue , 1997, Pages 171-184

  Wick, Georg ^a   Grubeck Loebenstein, Beatrix ^a  

^a ERICH SCHMID INSTITUTE OF MATERIALS SCIENCE   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

LIPID;

AGING; ALZHEIMER DISEASE; ANTIGEN PRESENTING CELL; ATHEROSCLEROSIS; B LYMPHOCYTE; DIETARY INTAKE; DISEASE COURSE; DISEASE SEVERITY; DRUG USE; ENVIRONMENTAL FACTOR; FAT INTAKE; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOREACTIVITY; MORBIDITY; PHYSICAL ACTIVITY; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; THYMUS; VACCINATION;

AGED; AGING; HUMANS; IMMUNITY; NUTRITION PHYSIOLOGY; VACCINATION;

EID: 0031448878     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-065X.1997.tb01037.x     Document Type: Review

References (113)

1. Buckley RH. Primary immunodeficiency diseases. In: Paul WE, ed. Fundamental immunology. New York: Raven Press, Ltd.; 1993. p. 1353-1374.
2. Ligthart GJ, et al. Admission criteria for immunogerontological studies in man: the SENIEUR protocol. Mech Ageing Dev 1984;28:47-55.
3. Reibnegger G, et al. Approach to define "normal aging" in man: immune function, serum lipids, lipoproteins and neopterin levels. Mech Ageing Dev 1988;46:67-82.
4. Traill KN, et al. Age-related changes in lymphocyte subset proportions, surface differentiation, antigen density and plasma membrane fluidity: application of the EURAGE SENIEUR protocol admission cirteria. Mech Ageing Dev 1985;33:39-66.
5. Wick G, Hu Y, Schwarz S, Kroemer G. Immunoendocrine communication via the hypothalamo-pituitary-adrenal axis in autoimmune diseases. Endocr Rev 1993;14:539-563.
6. Steinmann GG, Klaus B, Müller-Hermelink HK. The involution of the ageing human thymic epithelium is independent of puberty: a morphometric study. Scand J Immunol 1985;22:563-575.
7. Steinmann GG. The human thymus. Curr Top Pathol 1986;75:43-88.
8. George AJT, Ritter MA. Thymic involution with aging: obsolescence or good housekeeping? Immunol Today 1996;17:267-272.
9. Aspinall R. Age-associated thymic atrophy in the mouse is due to a deficiency affecting rearrangement of the TCR during intrathymic T cell development. J Immunol 1997;158:3037-3045.
10. Stulnig T, Maczek C, Böck G, Majdic O, Wick G. Reference intervals for human peripheral blood lymphocyte subpopulations from "healthy" young and aged subjects. Int Arch Allergy Immunol 1995;108:205-210.
11. Stein BE. Vaccinating elderly people: protecting from avoidable disease. Drug Aging 1994;5:242-253.
12. Goto M, Nishioka K. Age- and sex-related changes of the lymphocyte subsets in healthy individuals: an analysis by two-dimensional flow cytometry. J Gerontol 1989;44:M51-M56.
13. Utusyama M, et al. Differential age-change in the numbers of CD4+CD45RA+ and CD4+CD29+ T-cell subsets in human peripheral blood. Mech Ageing Dev 1992;63:57-68.
14. Song L, et al. Age-related effects in T cell activation and proliferation. Exp Gerontol 1993;28:313-321.
15. Huber LA, et al. Correlation of lymphocyte lipid composition membrane microviscosity and mitogen response in the aged. Eur J Immunol 1991;21:2761-2765.
16. Traill KN, Huber LA, Wick G, Jürgens G. Lipoprotein interactions with T cells: an update. Immunol Today 1990;11:411-417.
17. Fūlop T Jr, Leblanc C, Lacombe G, Dupuis G. Cellular distribution of protein kinase C isozymes in CD3-mediated stimulation of human T lymphocytes with aging. FEBS Lett 1995;375:69-74.
18. Ghosh J, Miller RA. Rapid tyrosine phosphorylation of Grb2 and She in T cells exposed to anti-CD3, anti-CD4, anti-CD45 stimuli: differential effects of aging. Mech Ageing Dev 1995;80:171-187.
19. Effros RB, et al. Decline in CD28+ T cells in centenarians and in long-term T cell cultures: a possible cause for both in vivo and in vitro immunosenescence. Exp Gerontol 1994;29:601-609.
20. Jackola DR, Hallgren HM. Diminished cell-cell binding by lymphocytes from healthy, elderly humans: evidence for altered activation of LFA-1 function with age. J Gerontol A Biol Sci Med Sci 1995;50:B368-B377.
21. Nagel JE, et al. Decreased proliferation, interleukin 2 synthesis, interleukin 2 receptor expression are accompanied by decreased mRNA expression in phytohemagglutinin-stimulated cells from elderly donors. J Clin Invest 1988;81:1096-1102.
22. Schwab R, Hausman PB, Rinnooy-Kan E, Weksler ME. Immunological studies of aging. X. Impaired T lymphocytes and normal monocyte response from elderly humans to the mitogenic antibodies OKT3 and Leu 4. Immunology 1985;55:677-684.
23. Gamble DA, Schwab R, Weksler ME, Szabo P. Decreased steady state c-myc mRNA in activated T cell cultures from old humans is caused by a smaller proportion of T cells that transcribe the c-myc gene. J Immunol 1990;144:3569-3573.
24. Wu W, Pahlavani M, Cheung HT, Richardson A. The effect of aging on the expression of interleukin 2 messenger ribonucleic acid. Cell Immunol 1986;100:224-231.
25. Pahlavani MA, Harris MD, Richardson A. The age-related decline in the induction of IL-2 transcription is correlated to changes in the transcription factor NFAT. Cell Immunol 1995;165:84-91.
26. Perillo NL, Naeim F, Walford RL, Effros RB. In vitro cellular aging in T-lymphocyte cultures: analysis of DNA content and cell size. Exp Cell Res 1993;207:131-135.
27. Globerson A. T lymphocytes and aging. Int Arch Allergy Immunol 1995;107:491-497.
28. Pawelec G, Adibzadeh M, Solana R, Beckman I. The T cell in the ageing individual. Mech Ageing Dev 1997;93:35-45.
29. Hayflick L, Moorhead PS. The serial cultivation of human diploid cell strains. Exp Cell Res 1961;25:585-621.
30. Perillo NL, Walford RL, Newman MA, Effros RB. Human lymphocytes possess a limited in vitro life span. Exp Gerontol 1989;24:177-187.
31. Effros RB, et al. Shortened telomeres in the expanded CD28- CD8+ cell subset in HIV disease implicate replicative senescence in HIV pathogenesis. AIDS 1996;10:F17-F22.
32. Grubeck-Loebenstein B, Lechner H, Trieb K. Long-term in vitro growth of human T cell clones: can postmitotic "senescent" cell populations be defined? Int Arch Allergy Immunol 1994;104:232-239.
33. Akbar AN, et al. The significance of low bcl-2 expression by CD45RO T cells in normal individuals and patients with acute viral infections: the role of apoptosis in T cell memory. J Exp Med 1993;178:427-438.
34. Lechner H, Amort M, Steger MM, Maczek C, Grubeck-Loebenstein B. Regulation of CD95 (APO-1) expression and the induction of apoptosis in human T cells: changes in old age. Int Arch Allergy Immunol 1996;110:238-243.
35. Pawelec G, Sansom D, Rehbein A, Adibzadeh M, Beckman I. Decreased proliferative capacity and increased susceptibility to activation-induced cell death in late-passage human CD4+ TCR2+ cultured T cell clones. Exp Gerontol 1996;6:655-668.
36. Effros RB, Pawelec G. Replicative senescence of T cells: does the Hayflick limit lead to immune exhaustion? Immunol Today 1997;18:450.
37. Walford RL, Jawaid SW, Naeim F. Evidence for in vitro senescence of T lymphocytes cultured from normal human peripheral blood. Age 1987;4:67-71.
38. McCarron M, Osborne Y, Story CJ, Dempsey IL, Tuner DR, Morley AA. Effect of age on lymphocyte proliferation. Mech Ageing Dev 1987;41:211-218.
39. Cossarizza A, et al. CD45 isoforms expression on CD4+ and CD8+ T cells throughout life, from newborns to centenarians: implications for T cell memory. Mech Ageing Dev 1996;86:173-195.
40. Posnett DN, Sinha R, Kabak S, Russo C. Clonal populations of T cells in normal elderly humans: the T cell equivalent to "benign monoclonal gammapathy". J Exp Med 1994;179:609-618.
41. + T cell clones in elderly humans. J Immunol 1997;158:4493-4499.
42. van Dijk-Härd I, Söderström I, Feld S, Holmberg D, Lundkvist I. Age-related impaired affinity maturation and differential D-JH gene usage in human VH6-expressing B lymphocytes from healthy individuals. Eur J Immunol 1997;27:1381-1386.
43. Miller RA. The aging immune system: primer and prospectus. Science 1996;273:70-74.
44. De la Fuenta M. Changes in the macrophage function with aging. Comp Biochem Physiol A Physiol 1985;81:935-938.
45. Beckman I, et al. T cell activation in the elderly: evidence for specific deficiencies in T cell/accessory cell interactions. Mech Ageing Dev 1990;51:265-276.
46. Rich EA, et al. Accessory function and properties of monocytes from healthy elderly humans for T lymphocyte responses to mitogen and antigen. Gerontology 1993;39:93-108.
47. Sprecher E, Becker Y, Kraal G, Hall E, Harrison D, Shultz LD. Effect of aging on epidermal DC populations in CD57BL/6J mice. J Invest Dermatol 1990;94:247-253.
48. Gilchrest BA, Murphy GF, Soter NA. Effect of chronological aging on Langerhans cells in the human epidermis. J Invest Dermatol 1982;79:85-88.
49. Komatsubara S, Cinader B, Muramatsu S. Functional competence of dendritic cells of ageing C57/BL/6 mice. Scand J Immunol 1986;24:517-525.
50. Fagiolo U, et al. Increased cytokine production in mononuclear cells of healthy elderly people. Eur J Immunol 1993;23:2375-2378.
51. Steger MM, Maczek C, Grubeck-Loebenstein B. Morphologically and functionally intact dendritic cells can be derived from the peripheral blood of aged individuals. Clin Exp Immunol 1996;105:544-551.
52. Xu Q, Jürgens G, Huber LA, Böck G, Wolf H, Wick G. Lipid utilization by human lymphocytes is correlated with high-density lipoprotein binding site activity. Biochem J 1992;285:105-112.
53. Jürgens G, et al. Promotion of lymphocyte growth by high density lipoproteins (HDL): physiological significance of the HDL binding site. J Biol Chem 1989;265:8549-8556.
54. Wick G, Huber LA, Xu Q, Jarosch E, Schönitzer D, Jürgens G. The decline of the immune response during aging: the role of an altered lipid metabolism. Ann N Y Acad Sci 1991;621:277-290.
55. Stulnig TM, Bühler E, Böck G, Kirchebner C, Schönitzer D, Wick G. Altered switch in lipid composition during T cell blast transformation in the healthy elderly. J Gerontol A Biol Sci Med Sci 1995;50A: 383-390.
56. Stulnig TM, et al. In vivo LDL receptor and HMG-CoA reductase regulation in human lymphocytes and its alterations during aging. Arterioscler Thromb Vasc Biol 1995;15: 872-878.
57. McGeer PL, McGeer EG. The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res Brain Res Rev 1995;21:195-218.
58. Glenner GG, Wong CW. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 1984;120:885-890.
59. McGeer PL, Akiyama H, Itagaki S, McGeer EG. Activation of the classical complement pathway in brain tissue of Alzheimer patients. Neurosci Lett 1989;107:341-346.
60. Itagaki S, Akiyama H, Saito H, McGeer PL. Ultrastructural localization of complement membrane attack complex (MAC)-like immuno-reactivity in brains of patients with Alzheimer's disease. Brain Res 1994;645:78-84.
61. Jiang H, Burdick D, Glabe CG, Cotman CW, Tenner AJ. Beta-amyloid activates complement by binding to a specific region of the collagen-like domain of the C1qA chain. J Immunol 1994;152:5050-5059.
62. Rogers J, et al. Complement activation by beta-amyloid in Alzheimer's disease. Proc Natl Acad Sci USA 1992;89: 10016-10020.
63. Paresce DM, Ghosh RN, Maxfield FR. Microglial cells internalize aggregates of the Alzheimer's disease amyloid β-protein via a scavenger receptor. Neuron 1996;17:553-565.
64. Maat-Schieman ML, Rozemuller AJ, van Duinen SG, Haan J, Eikelenboom P, Roos RA. Microglia in diffuse plaques in hereditary cerebral hemorrhage with amyloidosis. An immunohistochemical study. J Neuropathol Exp Neurol 1994;53: 483-491.
65. Itagaki S, McGeer PL, Akiyama H, Zhu S, Selkoe DJ. Relationship of microglia and astrocytes to amyloid deposits in Alzheimer's disease. J Neuroimmunol 1989;24:173-182.
66. McGeer PL, Kawamata T, Walker DG, Akiyama H, Tooyama I, McGeer EG. Microglia in degenerative neurological disease. Glia 1993;7:84-92.
67. Eikelenboom P, Zhan SS, Kamphorst W, van der Valk P, Rozemuller JM. Cellular and substrate adhesion molecules (integrins) and their ligands in cerebral amyloid plaques in Alzheimer's disease. Virchows Arch 1994;424:421-427.
68. Walker DG, Kim SU, McGeer PL. Complement and cytokine gene expression in cultured microglial derived from postmortem human brains. J Neurosci Res 1995;40:478-493.
69. Meda L, et al. Activation of microglial cells by β-amyloid protein and interferon-γ. Nature 1995;374:647-650.
70. Blasko I, Schmitt, TL, Steiner E, Trieb K, Grubeck-Loebenstein B. Tumor necrosis factor α augments amyloid β protein (25-35) induced apoptosis in human cells. Neurosci Lett (In press).
71. Gitter BD, Cox LM, Rydel RE, May PC. Amyloid β peptide potentiates cytokine secretion by interleukin-1β-activated human astrocytoma cells. Proc Natl Acad Sci USA 1995;92: 10738-10741.
72. 2+ accumulation. Proc Natl Acad Sci USA 1995;92:9328-9332.
73. Vassalli P. The pathophysiology of tumor necrosis factor. Annu Rev Immunol 1992;10:411-452.
74. Vasilakos J, Carroll R, Emmerling M. Interleukin 1β dissociates β-amyloid precursor protein and β-amyloid peptide secretion. FEBS Lett 1994;354:289-292.
75. Schmitt T, Steiner E, Klingler P, Sztankay A, Grubeck-Loebenstein B. The production of an amyloidogenic metabolite of the Alzheimer amyloid β precursor protein (APP) in thyroid cells is stimulated by interleukin 1β, but inhibited by interferon gamma. J Clin Endocrinol Metab 1996;81:1666-1669.
76. McGeer PL, McGeer EG, Rogers J, Sibley J. Anti-inflammatory drugs and Alzheimer's disease. Lancet 1990;335:1037.
77. McGeer PL, Schulzer M, McGeer EG. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology 1996;47:425-432.
78. Rogers J, et al. Clinical trial of indomethacin in Alzheimer's disease. Neurology 1993;43:1609-1611.
79. Percy ME. Peripheral biological markers as confirmatory or predictive tests for Alzheimer disease in the general population and in Down syndrome. In: Berg JM, Karlinsky H, Holland AJ, eds. Alzheimer disease. Down syndrome, and their relationship. Oxford, New York, Tokyo, Toronto: Oxford University Press; 1993. p. 199-223.
80. Moenning U, et al. Alzheimer amyloid β/A4 protein-reactive antibodies in human sera and CSF. In: Iqbal K, McLachlan D, Winblad B, Wisniewski H, eds. Alzheimer's disease: basic mechanisms, diagnosis and therapeutic strategies. Chichester: John Wiley & Sons; 1991. p. 557-776.
81. Gaskin F, Finley J, Fang Q, Xu S, Fu SM. Human antibodies reactive with β-amyloid protein in Alzheimer's disease. J Exp Med 1993;177:1181-1186.
82. Dickson DW, Rogers J. Neuroimmunology of Alzheimer's disease: a conference report. Neurobiol Aging 1992;13:793-798.
83. Grubeck-Loebenstein B, et al. Immunological features of nonimmunogenic hyperthyroidism. J Clin Endocrinol Metab 1985;60:150-155.
84. Grubeck-Loebenstein B, Londei M, Greenall C, Pirich K, Waldhäusl W, Feldmann M. Pathogenetic relevance of HLA class II expressing thyroid follicular cells in nontoxic goiter and in Graves' disease. J Clin Invest 1988;81:1608-1614.
85. Theyer G, et al. Phenotypic characterization of infiltrating leukocytes in benign prostatic hyperplasia. Lab Invest 1992;66:96-107.
86. Trieb K, Ransmayr G, Sgonc R, Lassmann H, Grubeck-Loebenstein B. APP peptides stimulate lymphocyte proliferation in normals, but not in patients with Alzheimer's disease. Neurobiol Aging 1996;17:541-547.
87. Schmitt TL, Sztankay A, Steiner E, Klingler P, Trieb K, Grubeck-Loebenstein B. Interferon γ inhibits production and metabolism of amyloid precursor protein in human extraneuronal cells. In: Iqbal K, Winblad B, Nishimura T, Takeda M, Wisniewski HM, eds. Alzheimer's disease: biology, diagnosis and therapeutics. Chichester: John Wiley & Sons; 1997. p. 431-437.
88. Ringheim GE, Szcepanik AM, Burgher KL, Petko W, Heroux JA, Cavalieri F. Transcriptional inhibition of the beta-amyloid precursor protein by interferon-gamma. Biochem Biophys Res Commun 1996; 224:246-251.
89. Bush AI, et al. An abnormality of plasma amyloid protein precursor in Alzheimer's disease. Ann Neurol 1992;32:57-65.
90. Iversen LL, Mortishire J, Pollack SJ, Shearman MS. The toxicity in vitro of β-amyloid protein. Biochem J 1995;311:1-16.
91. Schmitt TL, Steger M-M, Pavelka M, Grubeck-Loebenstein B. Interactions of the Alzheimer β amyloid fragment (25-35) with peripheral blood dendritic cells. Mech Ageing Dev 1997;94:223-232.
92. Wick G, Kleindienst R, Dietrich H, Xu Q. Is atherosclerosis an autoimmune disease? Trends Food Sci Technol 1992;3:114-119.
93. Wick G, Schett G, Amberger A, Kleindienst R, Xu Q. Is atherosclerosis an immunologically mediated disease? Immunol Today 1995;16:27-33.
94. Xu Q, Wick G. The role of heat shock proteins in protection and pathophysiology of the arterial wall. Mol Med Today 1996;2:372-379.
95. Xu Q, Oberhuber G, Gruschwitz M, Wick G. Immunology of atherosclerosis: cellular composition and major histocompatibility complex class II antigen expression in aortic intima, fatty streaks, atherosclerotic plaques in young and aged human specimens. Clin Immunol Immunopathol 1990;56: 344-359.
96. Kleindienst R, Xu Q, Willeit J, Waldenberger F, Weimann S, Wick G. Immunology of atherosclerosis: demonstration of heat shock protein 60 expression and T-lymphocytes bearing α/β or γ/δ receptor in human atherosclerotic lesions. Am J Pathol 1993;142:1927-1937.
97. Wick G, et al. Atherosclerosis, autoimmunity and the vascular associated lymphoid tissue (VALT). FASEB J 1997;11:1199-1207.
98. Ogra PS, Strober W, Mestecky J, McGhee JR, Lammaud ME, Bienenstock J, eds. Handbook of mucosal immunology. New York: Academic Press, Inc; 1994.
99. Xu Q, Kleindienst R, Waitz W, Dietrich H, Wick G. Increased expression of heat shock protein 65 coincides with a population of infiltrating T lymphocytes in atherosclerotic lesions of rabbits specifically responding to heat shock protein 65. J Clin Invest 1993;91:2693-2702.
100. Morimoto RI. Cells in stress: transcriptional activation of heat shock genes. Science 1993;259:1409-1410.
101. Young RA, Elliott TJ. Stress proteins, infection, and immune surveillance. Cell 1989;59:5-8.
102. Xu Q, et al. Induction of arteriosclerosis in normocholesterolemic rabbits by immunization with heat shock protein 65. Arterioscler Thromb 1992;12:789-799.
103. Xu Q, et al. Regression of arteriosclerotic lesions induced by immunization with heat shock protein 65-containing material in normocholesterolemic, but not hypercholesterolemic, rabbits. Atherosclerosis 1996;23:145-155.
104. Seitz CS, Kleindienst R, Xu Q, Wick G. Coexpression of intercellular adhesion molecule-1 and heat shock protein 60 is related to increased adherent monocytes and T cells on aortic endothelium of rats in response to endotoxin. Lab Invest 1996;74:241-252.
105. Amberger A, et al. Co-expression of ICAM-1, VCAM-1, ELAM-1 and Hsp60 in human arterial venous endothelial cells in response to cytokines and oxidized low density lipoproteins. Cell Stress Chaperones 1997;2:94-103.
106. Xu Q, et al. Association of serum antibodies to heat shock-protein 65 with carotid atherosclerosis. Lancet 1993;341:255-259.
107. Xu Q, Luef G, Weimann S, Gupta RS, Wolf H, Wick G. Staining of endothelial cells and macrophages in atherosclerotic lesions with human heat-shock protein reactive antisera. Arterioscler Thromb 1993;13:1763-1769.
108. Schett G, et al. Autoantibodies against heat shock protein 60 mediate endothelial cytotoxicity. J Clin Invest 1995;96:2569-2577.
109. Metzler B, et al. Epitope specificity of anti-heat shock protein 65/60 serum antibodies in atherosclerosis. Arterioscler Thromb Vasc Biol 1997;17: 536-541.
110. Begg NT. Immunoprophylaxis at extremes of age. J Antimicrob Chemother 1994;34:121-128.
111. Miller AE. Selective decline in cellular immune response to varicella-zoster in the elderly. Neurology 1980;30:582-587.
112. Huang YP, et al. In vitro T cell activation, in vitro defective IL-2 secretion, and response to influenza vaccination in elderly women. J Immunol 1992;148:715-722.
113. Steger MM, Maczek C, Berger P, Grubeck-Loebenstein B. Vaccination against tetanus in the elderly: do recommended vaccination strategies give sufficient protection? Lancet 1996;348ii: 762.